* Ocular Therapeutix submits amendment to potentially extend review for Dextenza New Drug Application (NDA)

* Ocular Therapeutix Inc - Requesting FDA to consider submission a major amendment and extend current NDA target action date of July 19, under PDUFA

* Ocular Therapeutix - extend current NDA target action date of July 19, under PDUFA by 3 months and to review submission during current review cycle

* Ocular Therapeutix Inc - Ocular Therapeutix submitted a close-out response to all inspectional observations included in FDA form 483

* Ocular Therapeutix Inc - submitted details of a manufacturing equipment change as an amendment to NDA resubmission for Dextenza 0.4 mg

* Ocular Therapeutix Inc - Ocular Therapeutix has modified a piece of manufacturing equipment referenced in NDA resubmission Source text for Eikon: Further company coverage: